J
Joerg Kreuzer
Researcher at Boehringer Ingelheim
Publications - 9
Citations - 330
Joerg Kreuzer is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Dabigatran & Warfarin. The author has an hindex of 6, co-authored 9 publications receiving 282 citations.
Papers
More filters
Journal ArticleDOI
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Charles V. Pollack,Paul A. Reilly,Richard A. Bernstein,Robert Dubiel,John W. Eikelboom,Stephan Glund,Menno V. Huisman,Elaine M. Hylek,Chak Wah Kam,Pieter Willem Kamphuisen,Joerg Kreuzer,Jerrold H. Levy,Frank W. Sellke,Joachim Stangier,Thorsten Steiner,Bushi Wang,Jeffrey I. Weitz +16 more
TL;DR: Re-VERSE AD is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention.
Journal ArticleDOI
Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.
Jackson Neville Colin,Dan Atar,Maria Borentain,Guenter Breithardt,Martin van Eickels,Matthias Endres,Uwe Fraass,Tim Friede,Hakima Hannachi,Salim Janmohamed,Joerg Kreuzer,Martin J Landray,Dominik Lautsch,Chantal Le Floch,Peter G. M. Mol,Huseyin Naci,Nilesh J. Samani,Anders Svensson,Cathrine Thorstensen,Jan G.P. Tijssen,Victoria Vandzhura,Andrew Zalewski,Paulus Kirchhof +22 more
TL;DR: A coordinated effort involving academia, regulators, industry, and payors will help to foster better and more effective conduct of clinical cardiovascular trials, supporting earlier availability of innovative therapies and better management of cardiovascular diseases.
Journal ArticleDOI
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
Samuel Z. Goldhaber,Henry Eriksson,Ajay K. Kakkar,Sebastian Schellong,Martin Feuring,Mandy Fraessdorf,Joerg Kreuzer,Elke Schueler,Sam Schulman +8 more
TL;DR: The efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS, and rates of bleeding events tended to be lower with dabig atran e Texilate than with warfarin, reaching statistical significance for any bleeding event.
Journal ArticleDOI
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
Samuel Z. Goldhaber,Sebastian Schellong,Ajay K. Kakkar,Henry Eriksson,Martin Feuring,Joerg Kreuzer,Mandy Fraessdorf,Sam Schulman +7 more
TL;DR: It is indicated that dabigatran is as effective as warfarin in preventing recurrent VTE, regardless of whether patients present with symptomatic pulmonary embolism with or without deep-vein thrombosis (DVT), orwith symptomatic DVT alone.
Journal ArticleDOI
Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™
Sam Schulman,Henry Eriksson,Samuel Z. Goldhaber,Ajay K. Kakkar,Clive Kearon,Sebastian Schellong,Martin Feuring,Jeffrey S. Friedman,Joerg Kreuzer +8 more
TL;DR: Treatment efficacy (DE versus warfarin) was not significantly affected by the presence of thrombophilia, and the frequencies of VTE/VTE-related deaths, and of PE, in patients with and without thromBophilia are shown in the Table.